



Demand for Medical 3D Models Drives Expansion for Materialise in the U.S.

December 2, 2015

PLYMOUTH, Mich., Dec. 2, 2015 /PRNewswire/ -- **Materialise NV (NASDAQ: MTLN)**, invests in additional medical production capacity in its US operations. The move strengthens the position of Materialise Mimics® Innovation Suite as a sophisticated medical backbone solution for healthcare professionals. Materialise's commitment to continuously improve the Mimics Innovation Suite has led to its increased use in hospitals, and other clinical settings and has driven expansion of Materialise operations in the U.S. market. The expansion further enables a complete range of powerful 3D surgical planning options to support patient-specific treatment, and the capacity to expediently provide anatomical models in the US market.



By providing virtual planning software linked with fully integrated Materialise 3D print services, clinicians and surgeons can use vital supplemental information to simulate or evaluate the best options for patient-specific treatment, and facilitate clear communication with patients, co-workers and/or surgical teams. Materialise HeartPrint, for instance, registered as a class 1 medical device in the US, aids cardiovascular specialists in helping plan patient care and select the necessary tools to treat complex cases such as congenital heart surgery or aortic aneurysm interventions.

Materialise continues to evolve its Mimics Innovation Suite capabilities and has made a new version of software that caters to clinicians with a desire to use 3D printing in their case planning. "As a beta participant for Materialise's latest medical software innovation, I have witnessed the power of their 25 years 'of experience in medical 3D printing with this software. Materialise is clearly focused on meeting the evolving needs of clinicians, and in being the software solution for the 3D printing process in hospitals." stated Frank Rybicki, MD, PhD., a long time Materialise collaborator.

"Unlike many existing products which only work with a limited number of the 3D printing solutions, Materialise's 510(k) cleared software connects to all 3D printing technologies. We are excited to expand our capacity, technology breadth and increase our responsiveness to the needs of clinicians. It is this focus that led our expansion in the U.S.," stated Bryan Crutchfield, Managing Director at Materialise USA.

Materialise has a 25 year track record of providing leading-edge, 3D visualization and printing solutions to their extensive list of hospital, academic and medical device customers. With all of these great minds working together, the future of patient-specific treatments is looking bright. For more information on Materialise software and solutions for Medical 3D Printing, visit biomedical.materialise.com.

About Materialise

With its headquarters in Leuven, Belgium, and branches worldwide, Materialise is a provider of Additive Manufacturing (AM) software solutions and sophisticated 3D printing services in a wide variety of industries, including healthcare, automotive, aerospace, art and design and consumer products. Materialise has been playing an active role in the field of AM since 1990, through its involvement in AM for industrial and medical applications, by providing biomedical and clinical solutions such as medical image processing and surgical simulations and by developing unique solutions for its customers' prototyping, production, and medical needs. For additional information, please visit: www.materialise.com.

Cautionary Statement on Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, the plans, objectives, expectations, strategies and prospects of the Company, both financial and business. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words "estimate," "expect," "anticipate," "project," "plan," "intend," "believe," "forecast," "will," "may," "could," "might", "aim", "should" and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the management's current expectations. These expectations, beliefs and projections are given in good faith and management believes there is a reasonable basis for them. However, the management cannot offer any assurance that its expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Management cautions readers that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. All of the forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. Management makes no commitment, and disclaims any duty to update or revise any forward-looking statements to reflect future events or changes in its expectations.

Photo - <http://photos.prnewswire.com/prnh/20151202/292633>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/demand-for-medical-3d-models-drives-expansion-for-materialise-in-the-us-300187047.html>

SOURCE Materialise NV

Vanessa Palsenborg, Corporate Communications Specialist, Phone: +32 16 39 66 37, Fax: +32 16 39 66 00, Email: press@materialise.com, Twitter: [@belgiancanuck](https://twitter.com/belgiancanuck) or [@MaterialiseNV](https://twitter.com/MaterialiseNV), Visit: www.materialise.com